APL 4098
Alternative Names: APL-4098Latest Information Update: 26 Jul 2024
At a glance
- Originator Apollo Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 04 Jun 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Australia (PO) (NCT06372717)
- 04 Jun 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy) in Australia (PO) (NCT06372717)
- 04 Jun 2024 Phase-I/II clinical trials in Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) in Australia (PO) (NCT06372717)